secwatch.observer — SEC 8-K summary
======================================

Issuer:     Checkpoint Therapeutics, Inc. (—)
CIK:        0001651407
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001104659-24-060882
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Checkpoint Therapeutics stockholders approve doubling authorized shares to 175M and expanding equity incentive plan
--------------------------------------------------------------------------------

- Stockholders approved increasing authorized common stock from 80M to 175M shares (95M increase).
- Amended 2015 Incentive Plan: shares reserved for issuance increased from 6M to 18M (12M increase).
- All seven director nominees elected with >95% support; KPMG ratified as auditor for FY2024.
- Advisory vote on executive compensation approved with 95% of votes cast in favor; three-year frequency approved.
- 79.4% of outstanding votes represented, establishing a quorum.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651407/000110465924060882/0001104659-24-060882-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651407/000110465924060882/tm2414353d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-060882

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer